Shares of Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) have been given an average recommendation of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $66.40.
Several equities analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. Wells Fargo & Company started coverage on Disc Medicine in a report on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 target price on the stock. Scotiabank assumed coverage on Disc Medicine in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $62.00 target price for the company. Jefferies Financial Group began coverage on shares of Disc Medicine in a research note on Wednesday. They set a “buy” rating and a $89.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Disc Medicine in a research note on Monday, September 16th.
View Our Latest Analysis on IRON
Institutional Trading of Disc Medicine
Disc Medicine Stock Up 0.0 %
NASDAQ IRON opened at $46.01 on Monday. The business has a 50-day moving average price of $48.92 and a 200-day moving average price of $42.06. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -13.61 and a beta of 0.59. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $77.60.
Disc Medicine (NASDAQ:IRON – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.08. Research analysts expect that Disc Medicine will post -4.19 EPS for the current fiscal year.
Disc Medicine Company Profile
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Featured Stories
- Five stocks we like better than Disc Medicine
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Texas Roadhouse Stock Steering for New Highs This Year
- What is a buyback in stocks? A comprehensive guide for investors
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 3 Small Caps With Big Return Potential
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.